Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice. Issue 1 (31st December 2023)

• Record Type: Journal Article
• Authors: Liu, Jianyang; He, Qian; Gao, Fan; Bian, Lianlian; Wang, Qian; An, Chaoqiang; Song, Lifang; Zhang, Jialu; Liu, Dong; Song, Ziyang; Li, Lu; Bai, Yu; Wang, Zhongfang; Liang, Zhenglun; Mao, Qunying; Xu, Miao
• Is Part Of: Emerging microbes & infections. Volume 12:Issue 1(2023)
• Publication Date: 2023-12-31
• Subjects: COVID-19 -- Omicron variant -- booster vaccine -- neutralizing antibody -- heterologous vaccination; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2022.2143283
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: Over one billion people have received 2–3 dosages of an inactivated COVID-19 vaccine for basic immunization. Whether a booster dose should be delivered to protect against the Omicron variant and its sub-lineages, remains controversial. Here, we tested different vaccine platforms targeting the ancestral or Omicron strain as a secondary booster of the ancestral inactivated vaccine in mice. We found that the Omicron-adapted inactivated viral vaccine promoted a neutralizing antibody response against Omicron in mice. Furthermore, heterologous immunization with COVID-19 vaccines based on different platforms remarkably elevated the levels of cross- neutralizing antibody against Omicron and its sub-lineages. Omicron-adapted vaccines based on heterologous platforms should be prioritized in future vaccination strategies to control COVID-19.